Another scam from the Davidson stable...
Message 19617460
Re: James Dale DAVIDSON/Agora, Inc.
It's interesting to note that in the SEC's amended complaint against Agora, Pirate Investor, and Frank Porter Stansberry, there is only one simple reference to James Dale DAVIDSON:
12. Agora, Inc. is a Maryland corporation based in Baltimore. Agora publishes books, magazines, newsletters and operates at least 15 financial web sites in the United States and Europe. Agora's publications include The Cutting Edge, Penny Stock Advisory, The Red Zone, Taipan, Rogue Trader, The Flying V Lockup Trader, CSX Trader, Fleet Street Letter, Options Hotline, Outstanding Investments, Richebacher Letter, Daily Reckoning Investment Advisory, Carpathia Letter, Strategic Opportunities, Jim DAVIDSON's Vantage Point Investing, and the Contrarian Speculator. Agora publications have well over 21,500 paid subscribers.
sec.gov
I see from a recent post on RB that DAVIDSON didn't take his naming by the SEC lying down (I wish I knew the date of it to see how well his predictions have panned out):
-----
By: baddogone0
20 Dec 2003, 09:32 PM EST
Msg. 2718 of 2724
Jump to msg. #
Dear Vantage Point Investor,
You may be as startled and upset as I am by the sudden collapse in the price of GeneMax (GMXX), which has tumbled in the last nine trading days. The question is, why? I can't pretend that I fully understand the answer. But I have a disturbing guess. It appears that the naked short-sellers who have counterfeited millions of GeneMax shares in an attempt to destroy the company have enlisted powerful help.
In theory, the Securities and Exchange Commission is a regulatory body charged with maintaining the integrity of public securities markets in the United States. In reality, the SEC is like any other government agency. It responds to powerful entrenched interests. It abhors bad publicity, rewards its friends and punishes its critics.
Unhappily, the SEC also lies. I know because the SEC field office in Utah has lied about me. And I suspect that these lies are the culmination of a carefully laid plan to discredit GeneMax and punish the company for raising troublesome issues about naked short selling, which has also embarrassed the SEC.
If you have been a subscriber to Vantage Point for any length of time, you are no doubt aware that I am a critic of "electronic counterfeiting," the process by which some investment banks, market makers and broker-dealers drive down the prices of Nasdaq Bulletin Board companies by selling unlimited quantities of shares they don't own. Since stock prices are determined by supply and demand, allowing unlimited counterfeiting of stock essentially guarantees that the stock becomes worthless.
Of course, a company whose shares are worthless won't last long. It is unable to raise money if its stock is worthless. All too often, such small companies are driven into oblivion by electronic counterfeiting. When we are slogging along with a weak economy, I consider it almost criminal negligence that the government would permit investment banks, market makers and broker-dealers to weaken the economy further by destroying small companies that could otherwise be a major fountain of growth.
Why would the government let this happen? I don't think it is necessarily a Grand Conspiracy with a capital "G." But the bad guys have managed to control most of the news about "electronic counterfeiting." And perversely, they also seem to have the regulators on their side.
I had a painful lesson in this reality at the beginning of this week when I learned to my astonishment that the Utah office of the SEC had tarnished my name by accusing me of failing to disclose an interest in two investments that I recommended in Vantage Point Investment Advisory. Their exact charge is as follows:
"Among the issuers promoted in this manner have been GeneMax Corp. and Endovasc Ltd., Inc. DAVIDSON is an officer, director and, indirectly, a substantial shareholder of these two issuers. Neither the soliciting e-mail nor the subsequent company report discloses DAVIDSON's relationship to the companies."
This is total rubbish. I deny any impropriety. Indeed, the charges are remote from the facts.
As you will know if you subscribed to Vantage Point last summer, I fully disclosed my role as a founder, director and officer of GeneMax when I recommended the company and its promising treatment for cancer. And I also disclosed a special relationship with Endovasc. I am not an officer or director of Endovasc. I have a few shares that I received in exchange for assigning my rights in what could be a valuable patent to the company.
To be sure that I wasn't missing something, I had my attorney review the record. He concluded that my disclosures are complete: "I spent this afternoon reviewing Agora marketing copy for Vantage Point and the newsletters and have verified that the charge that you failed to disclose your personal interest in GeneMax is completely false." Agora will be filing a motion to dismiss the SEC's baseless complaint.
I fail to see how anyone of good faith who reviewed the record could possibly construe it as the SEC apparently has. Although I can't prove it, I have concluded that the SEC, or at least some of its personnel, were more offended by my criticism of electronic counterfeiting than they are by the abuse itself -- which causes you and other investors hundreds of billions in losses. In fact, the costs of electronic counterfeiting are much higher than those entailed in the accounting scandals which have garnered so much attention. Nonetheless, instead of correcting these abuses, the SEC has gone out of its way to rope me into a doubtful complaint that they have developed against another Agora publication -- a product to which I have no connection other than a passive one as a minority shareholder in Agora.
Nor do I take it to be entirely a coincidence that while I have recommended more than 30 investments in Vantage Point over the past 16 months, my reputation is being tarred in respect to just two companies, GeneMax and Endovasc. These two companies have one thing in common, in addition to the fact that both have promising medical innovations that could ease much suffering and save many lives. Both have been at the forefront of legal action to combat the abuse of electronic counterfeiting of their shares. But these efforts have hardly earned them the friends they should. Rather than garnering applause, their efforts to confront the abuse of electronic counterfeiting of their shares has made both companies the focus of negative publicity.
In particular, one writer, Carol S. Remond, undertook to paint a negative picture of both companies, publishing what bordered on outright lies. For some reason known only to others, the SEC appears to have adopted Remond's text in defense of the electronic counterfeiters. In this respect, it is suggestive that the SEC apparently leaked its complaint about Agora to Remond, who cooperated by writing a story trumpeting the SEC's effort to discredit me and these good companies.
I wanted to write to you immediately when I got this startling news to tell you that I will not be cowed by these Machiavellian tactics. I will continue to raise important issues of investor protection that the SEC appears to wish to duck. I do so with faith that the truth will eventually triumph, the evil of electronic counterfeiting will be curtailed, and the integrity of public security markets restored.
Or to put it another way, if powerful people are so keen to discredit my criticism of electronic counterfeiting that they will orchestrate an entirely bogus charge of the kind carried on the wires against me this week, that itself indicates that more light needs to be shed on the shadowy activities they are trying to protect.
But, on to the status of your GeneMax holdings... Absolutely nothing about this company or its exciting immunotherapy development has changed and would warrant this share price decline. In fact, in an independent study commissioned by the company, it was determined that if GeneMax were funded as low as at $1.50 per share, and assuming that its products prove to work as well in humans as they have in animals, the present value of the stock would be $420 per share, notwithstanding dilution. GeneMax remains a fundamentally sound company and a tremendous buying opportunity at these levels. I recommend that you increase your GeneMax shares, as well as those in Endovasc (EVSC.OB). And, may I reiterate, I am a shareholder in both companies.
And, if you are as concerned as I am about electronic counterfeiting and its effects on the dynamic young companies that must fuel our country's future growth (as well as your portfolio), I urge you to write your congressman. You can also register your concern with the National Association Against Naked Short Selling (http://www.nakedshortselling.com),, which is taking up the fight for companies and investors alike.
Sincerely,
James DAVIDSON
ragingbull.lycos.com
=====
Here's what Our-Street had to say about the above:
He came right back in a subsequent newsletter and recommended to his subscribers that they each purchase $1,000 worth of a number of stocks he was touting including BEVsystems. The trouble with this is that he failed to tell his readers that he was a Director of the company and had been dumping shares as early as a few months prior to his May newsletter. DAVIDSON also failed to even disclose his ownership in ChampionLyte and if it hadn't been for an Our-Street.com inquiry to management of ChampionLyte, this fact may never have surfaced. Apparently Mr. DAVIDSON didn't feel the need to file the 13D that is customary at times like this.
Of course, Mr. DAVIDSON's involvement calls into question a certain transaction involving ChampionLyte. The supposed Cross Marketing or Joint Marketing agreement between ChampionLyte and BEVsystems in which BEVsystems gives ChampionLyte $125,000 worth of S-8 stock and ChampionLyte gives BEVsytems up to $100,000 in cash each and every month is a most questionable transaction and was never disclosed as a related party transaction despite Mr. DAVIDSON's obvious involvement in both companies.
The connections between ChampionLyte and BEVsystems go beyond this one agreement and Mr. DAVIDSON's heavy involvement in both companies. BEVsystems recently issued a significant amount of stock to a company that shares office space with ChampionLyte and which also shares an office address with Mr. Press' Finantra Capital.
our-street.com |
